OraSure Technologies, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carrie Eglinton Manner
- Full Time Employees
- 501
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 220 East First Street Bethlehem PA United States of America 18015
- IPO Date
- Nov 17, 1986
- CIK
- 0001116463
- Website
- orasure.com
- Similar Companies
- Business
- OraSure Technologies, Inc. develops, manufactures, and markets point-of-care diagnostic tests, sample collection devices, and laboratory services focused on infectious diseases, molecular diagnostics, and substance abuse detection; its core products include the OraQuick HIV self-test and in-home HIV antibody test, OraQuick HCV rapid antibody test, OraQuick In-Home COVID-19 antigen test, rapid assays for syphilis, Ebola, and other infectious diseases, Intercept oral fluid collection devices for drugs-of-abuse testing, IntelliSwab self-collection swabs, HEMAcollect blood collection devices, and microbiome analytical services through subsidiaries such as DNA Genotek, Diversigen, and Novosanis. The company serves clinical laboratories, hospitals, physicians' offices, public health organizations, government agencies, pharmaceutical firms, research institutions, and direct-to-consumer markets with rapid, non-invasive oral fluid and other sample-based solutions. OraSure Technologies operates globally with sales across the United States, Europe, and other international regions. Founded in 1988 and headquartered in Bethlehem, Pennsylvania, the company continues to expand through strategic acquisitions, including Sherlock Biosciences in late 2024 to enhance molecular diagnostics capabilities, GAIA Diagnostics in 2021 for infectious disease testing, and a definitive agreement announced in November 2025 to acquire BioMedomics for $4 million, adding Sickle SCAN rapid test for sickle cell disease to leverage existing international channels; it also renewed its HIV self-test program and received an unsolicited takeover bid from healthcare entrepreneur Ron Zwanziger in June 2025.
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
OraSure Announces First Quarter 2026 Financial Results
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies Appoints John D. Bertrand to its Board of Directors
OraSure Technologies (NASDAQ:OSUR) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why
OraSure Technologies (NASDAQ:OSUR) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
Agape ATP (NASDAQ:ATPC) vs. OraSure Technologies (NASDAQ:OSUR) Head to Head Survey
OraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates